ITCI Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 2.60%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $21,306,623.17

Intra-Cellular Therapies Insider Trading History Chart

Intra-Cellular Therapies Share Price & Price History

^$131.81

▲ +0.06 (0.05%)

As of 03/28/2025 05:00 PM ET

Days: 30 | 90 | 365

Intra-Cellular Therapies Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/4/2024	Sharon Mates	CEO	Sell	51,000	$85.80	$4,375,800.00	1,070,329
11/12/2024	Michael Halstead	President	Sell	22,869	$89.12	$2,038,085.28
8/30/2024	Sharon Mates	CEO	Sell	34,396	$72.84	$2,505,404.64	1,070,329
8/27/2024	Sharon Mates	CEO	Sell	40,513	$73.58	$2,980,946.54	1,070,329
8/23/2024	Sharon Mates	CEO	Sell	28,680	$74.46	$2,135,512.80	1,070,329
8/21/2024	Sharon Mates	CEO	Sell	53,013	$75.65	$4,010,433.45	1,070,329
8/16/2024	Mark Neumann	EVP	Sell	18,714	$75.08	$1,405,047.12	29,700
6/24/2024	Rory B. Riggs	Director	Sell	4,462	$75.57	$337,193.34	116,600
6/18/2024	Robert L. Van Nostrand	Director	Sell	20,000	$75.91	$1,518,200.00	9,690
3/11/2024	Lawrence J. Hineline	CFO	Sell	10,121	$65.96	$667,581.16
3/11/2024	Michael Halstead	EVP	Sell	7,345	$65.97	$484,549.65	19,803
3/11/2024	Sharon Mates	CEO	Sell	20,565	$65.21	$1,341,043.65	1,050,309
3/7/2024	Lawrence J. Hineline	CFO	Sell	13,132	$66.60	$874,591.20	29,700
3/7/2024	Sharon Mates	CEO	Sell	40,712	$66.50	$2,707,348.00	1,050,309
3/7/2024	Suresh K. Durgam	EVP	Sell	6,450	$66.56	$429,312.00	16,170
2/26/2024	Joel S. Marcus	Director	Sell	26,328	$68.68	$1,808,207.04	39,662
2/26/2024	Lawrence J. Hineline	CFO	Sell	13,337	$69.43	$925,987.91
2/26/2024	Michael Halstead	EVP	Sell	7,907	$69.53	$549,773.71	29,700
2/26/2024	Sharon Mates	CEO	Sell	22,590	$69.79	$1,576,556.10	1,050,309
1/18/2024	Sharon Mates	CEO	Sell	67,917	$65.19	$4,427,509.23	1,050,309
1/16/2024	Sharon Mates	CEO	Sell	75,361	$67.25	$5,068,027.25	1,050,309
1/11/2024	Michael Halstead	EVP	Sell	50,000	$66.83	$3,341,500.00
1/2/2024	Suresh K. Durgam	EVP	Sell	62,282	$70.60	$4,397,109.20
12/13/2023	Suresh K. Durgam	EVP	Sell	21,262	$65.00	$1,382,030.00
11/6/2023	Mark Neumann	EVP	Sell	42,393	$55.63	$2,358,322.59	29,700
9/18/2023	Sharon Mates	CEO	Sell	55,587	$53.76	$2,988,357.12	1,094,722
8/7/2023	Mark Neumann	EVP	Sell	55,300	$58.79	$3,251,087.00	45,339
7/17/2023	Suresh K. Durgam	EVP	Sell	1,842	$65.00	$119,730.00	21,262
6/14/2023	Lawrence J. Hineline	CFO	Sell	81,854	$63.97	$5,236,200.38
4/17/2023	Robert L. Van Nostrand	Director	Sell	10,000	$63.00	$630,000.00	9,345
3/28/2023	Mark Neumann	EVP	Sell	15,604	$54.31	$847,453.24	45,339
3/13/2023	Lawrence J. Hineline	CFO	Sell	5,582	$44.93	$250,799.26
3/13/2023	Sharon Mates	CEO	Sell	20,565	$44.99	$925,219.35	1,130,309
3/13/2023	Suresh K. Durgam	EVP	Sell	7,344	$45.04	$330,773.76	23,104
3/10/2023	Lawrence J. Hineline	CFO	Sell	15,663	$43.06	$674,448.78
3/10/2023	Mark Neumann	EVP	Sell	8,550	$43.34	$370,557.00	57,357
3/10/2023	Sharon Mates	CEO	Sell	41,770	$43.15	$1,802,375.50	1,130,309
3/1/2023	Mark Neumann	EVP	Sell	7,241	$50.01	$362,122.41	49,199
2/24/2023	Lawrence J. Hineline	CFO	Sell	7,455	$47.03	$350,608.65
2/24/2023	Mark Neumann	EVP	Sell	4,046	$47.12	$190,647.52	56,440
2/24/2023	Sharon Mates	CEO	Sell	22,590	$47.03	$1,062,407.70	1,100,309
2/24/2023	Suresh K. Durgam	SVP	Sell	7,906	$47.14	$372,688.84	23,104
2/21/2023	Lawrence J. Hineline	CFO	Sell	10,443	$46.82	$488,941.26
2/21/2023	Mark Neumann	EVP	Sell	3,898	$47.01	$183,244.98	52,580
2/21/2023	Sharon Mates	CEO	Sell	27,848	$46.83	$1,304,121.84	1,100,309
2/21/2023	Suresh K. Durgam	SVP	Sell	8,354	$46.84	$391,301.36	23,104
2/17/2023	Lawrence J. Hineline	CFO	Sell	53,968	$49.83	$2,689,225.44
12/19/2022	Joel S. Marcus	Director	Sell	5,000	$50.82	$254,100.00	29,233
12/13/2022	Sharon Mates	CEO	Sell	33,083	$55.00	$1,819,565.00	1,100,309
12/1/2022	Michael Halstead	EVP	Sell	50,000	$53.73	$2,686,500.00
9/21/2022	Lawrence J. Hineline	CFO	Sell	65,164	$45.63	$2,973,433.32
8/11/2022	Robert L. Van Nostrand	Director	Sell	30,000	$57.13	$1,713,900.00	9,043
5/12/2022	Joel S. Marcus	Director	Sell	10,000	$55.00	$550,000.00	54,233
4/8/2022	Mark Neumann	EVP	Sell	86,348	$64.37	$5,558,220.76	45,339

See Full Table

SEC Filings (Institutional Ownership Changes) for Intra-Cellular Therapies (NASDAQ:ITCI)

92.33% of Intra-Cellular Therapies stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Intra-Cellular Therapies Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
3/24/2025	Wellington Management Group LLP	1,033,743	$86.34M	0.0%	+1.6%	0.972%
3/18/2025	California State Teachers Retirement System	89,567	$7.48M	0.0%	-1.0%	0.084%
3/17/2025	Wealth Enhancement Advisory Services LLC	12,010	$1M	0.0%	+36.3%	0.011%
3/5/2025	Phocas Financial Corp.	19,058	$1.59M	0.2%	-0.9%	0.018%
2/28/2025	Universal Beteiligungs und Servicegesellschaft mbH	95,200	$7.95M	0.0%	N/A	0.090%
2/19/2025	GF Fund Management CO. LTD.	2,226	$0.19M	0.0%	N/A	0.002%
2/19/2025	Public Employees Retirement System of Ohio	83,080	$6.94M	0.0%	-8.2%	0.078%
2/18/2025	Castleark Management LLC	50,010	$4.18M	0.1%	-3.6%	0.047%
2/18/2025	Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A.	380,423	$31.77M	3.8%	-6.0%	0.358%
2/17/2025	UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC	335,319	$28.01M	0.0%	+3.7%	0.315%
2/17/2025	Squarepoint Ops LLC	150,176	$12.54M	0.0%	-47.8%	0.141%
2/17/2025	Two Sigma Advisers LP	143,267	$11.97M	0.0%	N/A	0.135%
2/17/2025	Two Sigma Investments LP	142,791	$11.93M	0.0%	+507.9%	0.134%
2/17/2025	Tidal Investments LLC	5,027	$0.42M	0.0%	+4.5%	0.005%
2/17/2025	Tema Etfs LLC	3,388	$0.28M	0.1%	N/A	0.003%
2/17/2025	Silvercrest Asset Management Group LLC	118,265	$9.88M	0.1%	-0.5%	0.111%
2/17/2025	Royal Bank of Canada	164,426	$13.73M	0.0%	+20.8%	0.155%
2/17/2025	Rafferty Asset Management LLC	4,230	$0.35M	0.0%	-27.3%	0.004%
2/17/2025	Raiffeisen Bank International AG	17,000	$1.42M	0.0%	N/A	0.016%
2/17/2025	Point72 Europe London LLP	38,961	$3.25M	0.2%	+101.0%	0.037%
2/17/2025	Point72 Hong Kong Ltd	2,840	$0.24M	0.0%	-54.9%	0.003%
2/17/2025	ProShare Advisors LLC	5,020	$0.42M	0.0%	-19.6%	0.005%
2/17/2025	Quantinno Capital Management LP	3,062	$0.26M	0.0%	N/A	0.003%
2/17/2025	Parkman Healthcare Partners LLC	243,123	$20.31M	2.7%	+0.6%	0.229%
2/17/2025	Patient Square Capital LP	71,990	$6.01M	2.2%	N/A	0.068%
2/17/2025	Man Group plc	48,597	$4.06M	0.0%	+76.7%	0.046%
2/17/2025	Nicholas Investment Partners LP	176,870	$14.77M	1.3%	+14.3%	0.166%
2/17/2025	Nuveen Asset Management LLC	519,253	$43.37M	0.0%	+6.4%	0.488%
2/17/2025	Occudo Quantitative Strategies LP	4,539	$0.38M	0.1%	N/A	0.004%
2/17/2025	OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC	20,284	$1.69M	0.1%	+17.0%	0.019%
2/17/2025	Orbimed Advisors LLC	163,000	$13.61M	0.3%	N/A	0.153%
2/17/2025	Millennium Management LLC	520,826	$43.50M	0.0%	+4.3%	0.490%
2/17/2025	Moore Capital Management LP	40,000	$3.34M	0.0%	N/A	0.038%
2/17/2025	Lazard Asset Management LLC	2,567	$0.21M	0.0%	-7.1%	0.002%
2/17/2025	LMR Partners LLP	8,177	$0.68M	0.0%	-73.8%	0.008%
2/17/2025	Hudson Bay Capital Management LP	65,049	$5.43M	0.0%	-18.7%	0.061%
2/17/2025	Gotham Asset Management LLC	11,007	$0.92M	0.0%	+15.8%	0.010%
2/17/2025	Graham Capital Management L.P.	3,200	$0.27M	0.0%	-18.7%	0.003%
2/17/2025	Granahan Investment Management LLC	69,841	$5.83M	0.2%	-29.8%	0.066%
2/17/2025	Ensign Peak Advisors Inc	29,562	$2.47M	0.0%	+4.6%	0.028%
2/17/2025	D. E. Shaw & Co. Inc.	534,461	$44.64M	0.0%	+45.0%	0.503%
2/17/2025	Deutsche Bank AG	776,028	$64.81M	0.0%	-10.5%	0.730%
2/17/2025	Driehaus Capital Management LLC	369,617	$30.87M	0.3%	+5.8%	0.348%
2/17/2025	Deep Track Capital LP	2,000,000	$167.04M	6.2%	+24.9%	1.881%
2/17/2025	Cubist Systematic Strategies LLC	156,335	$13.06M	0.1%	+29.5%	0.147%
2/17/2025	Cetera Investment Advisers	4,459	$0.37M	0.0%	+35.8%	0.004%
2/17/2025	Brevan Howard Capital Management LP	8,011	$0.67M	0.0%	-44.5%	0.008%
2/17/2025	Captrust Financial Advisors	9,656	$0.81M	0.0%	+20.0%	0.009%
2/17/2025	Balyasny Asset Management L.P.	139,660	$11.66M	0.0%	N/A	0.131%
2/17/2025	Baird Financial Group Inc.	64,474	$5.39M	0.0%	+35.0%	0.061%
2/17/2025	Bellevue Group AG	2,440,240	$203.81M	3.9%	-1.8%	2.295%
2/17/2025	Bank of America Corp DE	364,370	$30.43M	0.0%	-13.8%	0.343%
2/17/2025	BNP Paribas Financial Markets	42,310	$3.53M	0.0%	+69.8%	0.040%
2/17/2025	Ameriprise Financial Inc.	522,563	$43.64M	0.0%	-1.4%	0.492%
2/17/2025	Algert Global LLC	24,861	$2.08M	0.0%	-45.2%	0.023%
2/17/2025	Alyeska Investment Group L.P.	451,146	$37.68M	0.1%	-51.5%	0.424%
2/17/2025	Accredited Wealth Management LLC	335	$28K	0.0%	N/A	0.000%
2/17/2025	Ally Bridge Group NY LLC	147,750	$12.34M	10.4%	N/A	0.139%
2/14/2025	Mercer Global Advisors Inc. ADV	7,471	$0.62M	0.0%	N/A	0.007%
2/14/2025	Comerica Bank	211,130	$17.63M	0.1%	-0.2%	0.199%
2/14/2025	Schonfeld Strategic Advisors LLC	20,540	$1.72M	0.0%	-0.9%	0.019%
2/14/2025	AQR Capital Management LLC	536,781	$44.83M	0.1%	+16.2%	0.505%
2/14/2025	AdvisorShares Investments LLC	3,263	$0.27M	0.1%	+16.3%	0.003%
2/14/2025	Emerald Mutual Fund Advisers Trust	284,657	$23.78M	1.5%	-14.9%	0.268%
2/14/2025	Northern Trust Corp	609,777	$50.93M	0.0%	+24.0%	0.574%
2/14/2025	The Manufacturers Life Insurance Company	21,689	$1.81M	0.0%	-1.7%	0.020%
2/14/2025	Artia Global Partners LP	219,719	$18.35M	6.6%	+1.5%	0.207%
2/14/2025	Aquatic Capital Management LLC	5,206	$0.44M	0.0%	N/A	0.005%
2/14/2025	Susquehanna Fundamental Investments LLC	16,307	$1.36M	0.0%	N/A	0.015%
2/14/2025	Virtus ETF Advisers LLC	4,193	$0.35M	0.1%	-12.9%	0.004%
2/14/2025	Two Sigma Securities LLC	4,639	$0.39M	0.1%	N/A	0.004%
2/14/2025	Nebula Research & Development LLC	31,781	$2.65M	0.3%	+44.2%	0.030%
2/14/2025	Lord Abbett & CO. LLC	516,719	$43.16M	0.1%	-17.8%	0.486%
2/14/2025	Voya Investment Management LLC	85,411	$7.13M	0.0%	+13.9%	0.080%
2/14/2025	Adage Capital Partners GP L.L.C.	678,000	$56.63M	0.1%	+266.5%	0.638%
2/14/2025	Hood River Capital Management LLC	615,161	$51.38M	0.8%	+2.5%	0.579%
2/14/2025	Price T Rowe Associates Inc. MD	589,906	$49.27M	0.0%	-43.4%	0.555%
2/14/2025	Silverarc Capital Management LLC	179,085	$14.96M	3.3%	+7.2%	0.168%
2/14/2025	ClearAlpha Technologies LP	3,981	$0.33M	0.2%	N/A	0.004%
2/14/2025	J. Safra Sarasin Holding AG	30,564	$2.55M	0.0%	+9.7%	0.029%
2/14/2025	Stifel Financial Corp	34,210	$2.86M	0.0%	+3.0%	0.032%
2/14/2025	OneDigital Investment Advisors LLC	3,772	$0.32M	0.0%	-4.7%	0.004%
2/14/2025	Tower Research Capital LLC TRC	15,840	$1.32M	0.0%	+6,555.5%	0.015%
2/14/2025	MetLife Investment Management LLC	6,343	$0.53M	0.0%	-2.2%	0.006%
2/14/2025	Natixis	549	$46K	0.0%	-24.5%	0.001%
2/14/2025	Dimensional Fund Advisors LP	84,391	$7.05M	0.0%	+1.4%	0.079%
2/14/2025	First Trust Advisors LP	766,134	$63.99M	0.1%	+12.6%	0.721%
2/14/2025	Commerce Bank	7,092	$0.59M	0.0%	+6.8%	0.007%
2/14/2025	1492 Capital Management LLC	52,537	$4.39M	2.1%	-0.6%	0.049%
2/14/2025	Alpha DNA Investment Management LLC	5,797	$0.48M	0.2%	N/A	0.005%
2/14/2025	Altium Capital Management LLC	75,000	$6.26M	1.8%	-51.3%	0.071%
2/13/2025	CANADA LIFE ASSURANCE Co	22,436	$1.87M	0.0%	+4.4%	0.021%
2/13/2025	Canada Pension Plan Investment Board	179,000	$14.95M	0.0%	-5.3%	0.168%
2/13/2025	Marshall Wace LLP	1,079,757	$90.18M	0.1%	-7.0%	1.016%
2/13/2025	Wasatch Advisors LP	3,248,821	$271.34M	1.3%	-15.6%	3.056%
2/13/2025	PEAK6 LLC	3,000	$0.25M	0.0%	N/A	0.003%
2/13/2025	Regal Investment Advisors LLC	7,243	$0.61M	0.0%	-1.2%	0.007%
2/13/2025	Jump Financial LLC	65,109	$5.44M	0.1%	+14.9%	0.061%
2/13/2025	Guggenheim Capital LLC	30,119	$2.52M	0.0%	-19.1%	0.028%
2/13/2025	Walleye Capital LLC	383,591	$32.04M	0.1%	+49.5%	0.361%

Data available starting January 2016

See Full Table

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Today's Range

Now: $131.81

$131.79

$131.87

50 Day Range

MA: $129.12

$126.20

$131.81

52 Week Range

Now: $131.81

$64.09

$131.87

Volume

1,584,630 shs

Average Volume

1,391,525 shs

Market Capitalization

$14.04 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.69

Who are the company insiders with the largest holdings of Intra-Cellular Therapies?: Intra-Cellular Therapies' top insider shareholders include:
Sharon Mates (CEO)
Rory B Riggs (Director)
Mark Neumann (EVP)
Joel S Marcus (Director)
Lawrence J Hineline (CFO)
Michael Halstead (EVP)
Suresh K Durgam (EVP)
Nostrand Robert L Van (Director)
Michael Halstead (President)
Suresh K Durgam (EVP)
Learn More about top insider investors at Intra-Cellular Therapies.
Who are the major institutional investors of Intra-Cellular Therapies?: Intra-Cellular Therapies' top institutional shareholders include:
FMR LLC — 10.42%
Vanguard Group Inc. — 9.14%
JPMorgan Chase & Co. — 4.82%
Wasatch Advisors LP — 3.06%
Norges Bank — 3.02%
Invesco Ltd. — 2.89%
Learn More about top institutional investors of Intra-Cellular Therapies stock.
Which institutional investors are selling Intra-Cellular Therapies stock?: In the previous quarter, ITCI stock was sold by these institutional investors:
Wasatch Advisors LP
Alyeska Investment Group L.P.
Price T Rowe Associates Inc. MD
Schroder Investment Management Group
JPMorgan Chase & Co.
Alliancebernstein L.P.
Squarepoint Ops LLC
Lord Abbett & CO. LLC
During the last year, company insiders that have sold Intra-Cellular Therapies company stock include:
Sharon Mates (CEO)
Rory B Riggs (Director)
Mark Neumann (EVP)
Joel S Marcus (Director)
Lawrence J Hineline (CFO)
Learn More investors selling Intra-Cellular Therapies stock.
Which institutional investors are buying Intra-Cellular Therapies stock?: During the last quarter, ITCI stock was acquired by institutional investors including:
Norges Bank
Raymond James Financial Inc.
Adage Capital Partners GP L.L.C.
TimesSquare Capital Management LLC
Deep Track Capital LP
D. E. Shaw & Co. Inc.
Orbimed Advisors LLC
Ally Bridge Group NY LLC